| Drug ID: | Drug81 |
|---|---|
| Drug Name: | Terbinafine |
| CID: | 1549008 |
| DrugBank ID: | DB00857 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT02606032 |
| Molecular Formula: | C21H25N |
| Molecular Weight: | 291.4 g/mol |
| Isomeric SMILES: | CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21 |
| Synonyms: | terbinafine; 91161-71-6; Lamasil; Lamisil Tablet; Terbinafina; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; Terbinafinum; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; UNII-G7RIW8S0XP; G7RIW8S0XP |
| Phase 0: | 1 |
| Phase 1: | 26 |
| Phase 2: | 16 |
| Phase 3: | 18 |
| Phase 4: | 1 |
| Description: | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal. It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (squalene 2,3-epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt685 | 1549008 | Terbinafine | 1565 | CYP2D6 | Homo sapiens (human) | None | |
| dt686 | 1549008 | Terbinafine | 4363 | ABCC1 | Homo sapiens (human) | 18466103 | ABCC1 affects the susceptibility to terbinafine |
| dt687 | 1549008 | Terbinafine | 1244 | ABCC2 | Homo sapiens (human) | 18466103 | ABCC2 affects the susceptibility to terbinafine |
| dt688 | 1549008 | Terbinafine | 6347 | CCL2 | Homo sapiens (human) | 16784723 | Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]|ptger2 protein promotes the reaction [terbinafine inhibits the reaction [TNF protein results in increased expre |
| dt689 | 1549008 | Terbinafine | 10850 | CCL27 | Homo sapiens (human) | 16784723 | PTGER3 protein promotes the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]|terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 mrna]|ptger2 protein promotes t |
| dt690 | 1549008 | Terbinafine | 6352 | CCL5 | Homo sapiens (human) | 16784723 | PTGER2 protein promotes the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]|ptger3 protein promotes the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of |
| dt691 | 1549008 | Terbinafine | 6352 | CCL5 | Homo sapiens (human) | 23688403 | Terbinafine inhibits the reaction [[poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mrna] |
| dt692 | 1549008 | Terbinafine | 3627 | CXCL10 | Homo sapiens (human) | 24471457 | Terbinafine inhibits the reaction [biological products results in increased expression of CXCL10 protein]|terbinafine inhibits the reaction [biological products results in increased expression of CXCL10 mrna] |
| dt693 | 1549008 | Terbinafine | 3576 | CXCL8 | Homo sapiens (human) | 23688403 | Terbinafine inhibits the reaction [[poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mrna] |
| dt694 | 1549008 | Terbinafine | 3576 | CXCL8 | Homo sapiens (human) | 20816994 | U 0126 inhibits the reaction [terbinafine results in increased expression of CXCL8 protein]|terbinafine results in increased expression of CXCL8 protein |
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02606032 | Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis | PHASE2 | COMPLETED | Hamilton Health Sciences Corporation | Ulcerative Colitis | DRUG: Metronidazole|DRUG: Doxycycline|DRUG: Terbi… | Details |
| NCT05119712 | Terbinafine Treatment of Axial Spondyloarthropathy | EARLY_PHASE1 | Not recruiting | Oregon Health and Science University | Ankylosing Spondylitis;Axial Spondyloarthritis;Ps… | Drug: Terbinafine Tablets;Diagnostic Test: Labora… | Details |
| NCT05049525 | Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease Not Responding Adequately to Current Therapy | PHASE2 | Not recruiting | Montreal Heart Institute | Crohn's Disease;Inflammatory Bowel Diseases | Drug: Itraconazole 400 mg/day and terbinafine 500… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations